MiNK Therapeutics, Inc.

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing novel cell-based immunotherapies using its proprietary iNKT (invariant Natural Killer T) cell platform. The company designs adoptive cell therapies that isolate, process, and expand patient or donor-derived iNKT cells for treatment of serious diseases including graft-versus-host disease, solid tumors, and multiple myeloma, with its lead candidate agenT-797 being investigated across multiple clinical trial settings. As a pre-revenue company, MiNK is funded through capital raises and research support from its parent company Agenus, relies on in-licensed intellectual property, and maintains in-house manufacturing capabilities supplemented by contract manufacturers, with future revenues dependent on successful clinical development, regulatory approval, and commercialization of its product candidates in a competitive landscape dominated by larger pharmaceutical and biotechnology firms.